Venus Concept Inc Stock Price, News & Analysis

Venus Concept, a leader in medical aesthetic technology, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Management's presentation will be available on-demand starting September 13 at 7:00 a.m. Eastern Time. Additionally, virtual investor meetings are scheduled for September 14. The presentation can be accessed via the Company's investor relations website, with a replay available post-conference. Venus Concept operates in over 60 countries, offering a range of minimally and non-invasively aesthetic and hair restoration technologies.

Venus Concept (NASDAQ: VERO) reported robust Q2 2021 financial results, with total revenue of $25.8 million, a 52% increase year-over-year. The company's gross margin improved to 72.5%, and GAAP operating income surged by 117% to $1.5 million. Net income also saw a significant rise, reaching $0.4 million. The company upgraded its full-year revenue guidance to between $102.0 million and $107.0 million, representing a projected growth of 31% to 37%. Recent product developments and collaborations further bolster its market position.

Venus Concept, a leader in medical aesthetic technology, announced its participation in the Sidoti & Co. Microcap Conference to be held virtually on August 18-19, 2021. Management will present on August 18 at 8:30 a.m. ET. An audio webcast of the presentation will be available on the Company's investor relations website, with an archive for later replay.

With a diverse product range, including minimally invasive aesthetic devices and hair restoration systems, Venus Concept operates in over 60 countries. The Company favors a subscription-based sales model in North America and direct markets.

Venus Concept (NASDAQ: VERO) has received a medical device license from Health Canada to market the Venus Fiore Feminine Health System. This follows the CE Mark received in March 2020. The limited launch in Canada and the EU is expected in Q3 2021.

The Venus Fiore system uniquely addresses feminine health issues, providing three non-surgical treatments: internal vaginal, labia tightening, and mons pubis skin tightening. Designed for post-menopausal women, it aims to enhance sexual quality of life and improve physical appearance.

Venus Concept, a leader in medical aesthetic technology, will participate in the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 2:30 p.m. ET. An audio webcast of the presentation will be available on the company’s investor relations website, with an archive for later access.

The company operates a subscription-based business model, offering a wide range of devices for minimally invasive and non-invasive aesthetic treatments and hair restoration systems worldwide.

Venus Concept (NASDAQ: VERO) will announce its second quarter financial results for fiscal year 2021 on August 13, 2021, before market open. A conference call to discuss these results will occur at 8:00 a.m. ET the same day, with a Q&A session to follow. Interested parties may join by dialing 877-407-2991, or view the live webcast on the company's investor relations site. Venus Concept is recognized for its wide range of minimally invasive and non-invasive aesthetic technologies across over 60 countries, supporting a subscription-based sales model in North America.

Venus Concept (NASDAQ: VERO) reported a 56% increase in total revenue for Q1 2021, reaching $22.6 million compared to $14.5 million in Q1 2020. The company's gross margin improved to 67.4% from 64.0%, while the GAAP operating loss significantly decreased to $6.8 million from $43.6 million year-over-year. Adjusted EBITDA loss decreased 63% to $5.0 million. The company revised its 2021 revenue guidance to $100 million to $105 million, an anticipated growth of 28% to 35%.

Venus Concept (NASDAQ: VERO) announced its financial results for Q1 fiscal year 2021 will be released on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET to discuss these results, with participation details provided for both domestic and international callers. The call will also be available via a live webcast and archived for later access. Venus Concept is known for its innovative medical aesthetic technologies, operating in over 60 countries with a subscription-based sales model.

Venus Concept (NASDAQ: VERO) reported Q4 2020 revenue of $25.8 million, down 19% YoY from $31.9 million, impacted by COVID-19. However, it marked a 25% increase from Q3 2020's $20.7 million. The operating loss decreased by 42% YoY to $10.3 million, with a net loss of $15.0 million, improving from $22.7 million in Q4 2019. Adjusted EBITDA loss was $2.4 million, compared to $11.5 million the previous year. For 2021, guidance suggests revenue growth of 26% to 32%, assuming no significant COVID-19 resurgence. Cash stood at $34.4 million as of December 31, 2020.